



**Universiteit
Leiden**
The Netherlands

Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants

Oosten, L. van; Altenburg, J.J.; Fougereux, C.; Geertsema, C.; End, F. van den; Evers, W.A.C.; ... ; Pijlman, G.P.

Citation


Oosten, L. van, Altenburg, J. J., Fougereux, C., Geertsema, C., End, F. van den, Evers, W. A. C., ... Pijlman, G. P. (2021). Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants. *Mbio*, 12(5). doi:10.1128/mBio.01813-21

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3264393>

Note: To cite this publication please use the final published version (if applicable).



Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants

Linda van Oosten,^a Jort J. Altenburg,^b Cyrielle Fougeroux,^c Corinne Geertsema,^a Fred van den End,^b Wendy A. C. Evers,^b Adrie H. Westphal,^d Simon Lindhoud,^d Willy van den Berg,^d Daan C. Swarts,^d Laurens Deurhof,^e Andreas Suhrbier,^f Thuy T. Le,^f Shessy Torres Morales,^g Sebenzile K. Myeni,^g Marjolein Kikkert,^g Adam F. Sander,^{c,h} Willem Adriaan de Jongh,^{c,h} Robert Dagil,^h Morten A. Nielsen,^h Ali Salanti,^h Max Søgaard,ⁱ Timo M. P. Keijzer,^j Dolf Weijers,^d Michel H. M. Eppink,^b René H. Wijffels,^b Monique M. van Oers,^a Dirk E. Martens,^b  Gorben P. Pijlman^a

^aLaboratory of Virology, Wageningen University, Wageningen, The Netherlands

^bBioprocess Engineering, Wageningen University, Wageningen, The Netherlands

^cAdaptVac Aps, Hørsholm, Denmark

^dLaboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands

^eLaboratory of Phytopathology, Wageningen University, Wageningen, The Netherlands

^fQIMR Berghofer Medical Research Institute, Brisbane, Australia

^gDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

^hCentre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

ⁱExpreS2ion Biotechnologies Aps, Hørsholm, Denmark

^jApplikon Biotechnology BV, Delft, The Netherlands

ABSTRACT Vaccines pave the way out of the SARS-CoV-2 pandemic. Besides mRNA and adenoviral vector vaccines, effective protein-based vaccines are needed for immunization against current and emerging variants. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. Since subunit S only partially protected mice from SARS-CoV-2 challenge, we produced S1 for conjugation to bacteriophage AP205 VLP nanoparticles using tag/catcher technology. The S1 yield in an insect-cell bioreactor was ~11 mg/liter, and authentic protein folding, efficient glycosylation, partial trimerization, and ACE2 receptor binding was confirmed. Prime-boost immunization of mice with 0.5 μg S1-VLPs showed potent neutralizing antibody responses against Wuhan and UK/B.1.1.7 SARS-CoV-2 variants. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.

IMPORTANCE Vaccination is essential to reduce disease severity and limit the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Protein-based vaccines are useful to vaccinate the world population and to boost immunity against emerging variants. Their safety profiles, production costs, and vaccine storage temperatures are advantageous compared to mRNA and adenovirus vector vaccines. Here, we use the versatile and scalable baculovirus expression vector system to generate a two-component nanoparticle vaccine to induce potent neutralizing antibody responses against SARS-CoV-2 variants. These nanoparticle vaccines can be quickly adapted as boosters by simply updating the antigen component.

KEYWORDS SARS-CoV-2, insect cells, nanoparticle, vaccines

Citation van Oosten L, Altenburg JJ, Fougeroux C, Geertsema C, van den End F, Evers WAC, Westphal AH, Lindhoud S, van den Berg W, Swarts DC, Deurhof L, Suhrbier A, Le TT, Torres Morales S, Myeni SK, Kikkert M, Sander AF, de Jongh WA, Dagil R, Nielsen MA, Salanti A, Søgaard M, Keijzer TMP, Weijers D, Eppink MHM, Wijffels RH, van Oers MM, Martens DE, Pijlman GP. 2021. Two-component nanoparticle vaccine displaying glycosylated spike S1 domain induces neutralizing antibody response against SARS-CoV-2 variants. *mBio* 12:e01813-21. <https://doi.org/10.1128/mBio.01813-21>.

Editor John T. Patton, Indiana University Bloomington

Copyright © 2021 van Oosten et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Gorben P. Pijlman, gorben.pijlman@wur.nl.

Received 21 June 2021

Accepted 14 September 2021

Published 12 October 2021

Vaccination has become a key instrument in the fight against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, which was declared a pandemic by the World Health Organization in March 2020. Within 6 months, the coronavirus disease 19 (COVID-19) had claimed the lives of one million people (<https://covid19.who.int>). Despite global efforts to restrict the viral spread through economic and social interventions, the virus continues to put a substantial strain on economies and health care systems around the world. Large-scale vaccination programs have proven to be critical in reducing the viral spread and preventing severe disease (1).

The envelope of the SARS-CoV-2 virion contains membrane and spike (S) proteins. The S protein is a trimeric glycoprotein involved in virion attachment and entry into host cells. S is divided into two domains, S1 and S2, by a furin protease cleavage site (2, 3). S1 contains the receptor-binding domain (RBD) that binds the human angiotensin 2 (hACE2) receptor, whereas the fusion peptide (FP) is found in S2 (4, 5). Since S is indispensable for virus entry and is highly immunogenic, it is the main target in vaccine design to induce antibody-mediated virus neutralization in immunized individuals (6, 7). In many vaccine development studies, S is stabilized in its prefusion state by eliminating the furin cleavage site and inserting a stabilizing diproline mutation in S2 (3, 8–10).

At unprecedented speed, multiple COVID-19 vaccines have entered the market via emergency approvals from, among others, the European Medicines Agency and the U.S. Food and Drug Administration. These early vaccines, which are based on mRNA or adenoviral vectors, have been shown to be effective in preventing COVID-19 infection (11–13). Recombinant subunit vaccines based on recombinant S protein are currently in late-stage clinical trials and have been shown to induce potent neutralizing antibody (nAb) responses in nonhuman primates (14–16) and humans in phase II and III clinical trials (17).

The recent emergence of SARS-CoV-2 variants (<https://nextstrain.org/sars-cov-2>) highlights the importance of a robust vaccine production platform with good scalability and modularity for rapid adaptation to novel variants. For the production of recombinant proteins, the insect cell-baculovirus expression vector system (IC-BEVS) is a well-established platform. It is used for (commercial) producing virus-like particles (VLPs; human papillomavirus; Cervarix, GlaxoSmithKline), proteins with complex post-translational modifications, including glycoproteins (influenza A virus hemagglutinin; FluBlok; Sanofi), and difficult-to-produce protein complexes (18, 19). IC-BEVS has been used to produce coronavirus spike proteins of SARS-CoV (20) and Middle East respiratory syndrome-coronavirus (MERS-CoV) (9, 21, 22) as well as SARS-CoV-2 spikes in structural studies (23–27) and as subunit vaccines (28, 29). The IC-BEVS is rapidly scalable up to a million doses using insect cell bioreactors with working volumes of a few thousand liters in animal component-free medium (18, 30, 31). Furthermore, protein-based vaccines offer a very high safety profile, since millions of people have been vaccinated with IC-BEVS-produced proteins (Cervarix, FluBlok) without experiencing any severe adverse effects (31, 32). Therefore, IC-BEVS would be well-suited for producing SARS-CoV-2 vaccines.

A potential shortcoming for such subunit vaccines is their relatively low immunogenicity that can be compensated for by the addition of adjuvants and/or sequential immunizations (boosters). This has also been demonstrated in the case of SARS-CoV-2 RBD immunization (33, 34) and prefusion stabilized S (35). The immunogenicity of subunit vaccines can be improved by the presentation of antigens on nanoparticles or VLPs. The unidirectional display of antigens and the size of the particles more closely resemble that of a virus and result in increased B-cell responses by cross-presentation of epitopes, resulting in enhanced processing by antigen-presenting cells (APC) and B-cell receptors (36–38). Moreover, VLPs are replication-deficient because they do not contain genetic material from the originating virus and, thus, are considered safe (39). The licensed human papillomavirus vaccine (Cervarix; GSK) is a VLP made with the IC-BEVS that provides long-lived protective immunity after just one dose (40, 41).

Experimental SARS-CoV-2 VLP and nanoparticle vaccines have also been developed and have demonstrated their potential to induce protection against disease with low doses (14, 42–44).

In this study, we use the AP205 VLP and tag/catcher system to construct a baculovirus-derived SARS-CoV-2 vaccine based on the S1 subunit. Covalent conjugation of antigens on the VLP surface can be achieved by the Spytag/Spycatcher platform (45, 46). This plug-and-display technology is based on a bacterial adhesin that has been split genetically into a tag and catcher peptide, which forms a covalent bond upon mixing (47). Even without adjuvant, AP205 VLPs decorated with antigens have been found to induce robust immune responses at a single dose (48, 49). Recently, the RBD domain of SARS-CoV-2 was coupled to these VLPs using a proprietary split-protein tag/catcher technology, resulting in robust neutralizing antibody production in mice (34), and has been further developed into a phase I/II clinical study.

Using the IC-BEVS, we demonstrate insect cell-mediated production and purification of (i) the full-length spike protein, (ii) a secreted form of a prefusion-stabilized spike, and (iii) a secreted form of the SARS-CoV-2 S1 domain. We formulated the secreted S as an adjuvanted subunit vaccine and tested protection of K18-hACE2 mice from SARS-CoV-2 challenge. We also fused the S1 domain to the split-protein tag and displayed this on AP205 VLPs. Mice vaccinated with the S1-VLP vaccine had strong immune responses and neutralizing antibodies against both the Wuhan SARS-CoV-2 and the UK/B.1.1.7 variant (VOC-202012/01) that was predominant in Europe.

RESULTS

Baculovirus expression and localization of SARS-CoV-2 spikes in Sf9 insect cells.

To determine the most suitable recombinant baculovirus system to produce SARS-CoV-2 spike variants and to determine the most suitable secretion signal sequence, Sf9 cells were infected with AcBACe56 and AcOET recombinant baculoviruses encoding the SARS-CoV-2 spike (Fig. 1a). The spike proteins were similarly expressed in the cells with either the N-terminal HBM signal sequence or the baculovirus GP64 signal sequence (Fig. 1b, compare Sp1 with Sp2). Furthermore, the AcBACe56 and AcOET recombinant baculoviruses induced expression of S proteins that were recognized by convalescent-phase sera from COVID-19 patients (Fig. 1b). Baculovirus encoding GFP (AcGFP) and mock-infected Sf9 cells were included as controls and were not detected by the same sera. As expected, removal of the C-terminal transmembrane (CT) domain from the spike protein lowered the detection signal, since S was now excreted from the cells (Fig. 1b, AcOET-Sp9). Compared to AcOET, our in-house AcBACe56 produced similar yields of secreted S (see Fig. S1 in the supplemental material). Generation of recombinant AcOET baculovirus stocks demands less hands-on time than AcBACe56. Therefore, AcOET-Sp9 was used for further production and purification of secreted S.

Immunogenicity of a SARS-CoV-2 subunit vaccine from insect cells. The prefusion-stabilized S was produced with AcOET-Sp9 baculoviruses in ExpiSf9 cells cultured in shake flasks in chemically defined medium. After purification, the recombinant protein yield was estimated to be 180 μg S protein per liter of culture fluid with relatively low purity (Fig. 2a). The insect cell proteins in the culture fluid contaminated the S protein and could not be removed with a single purification step. We subsequently used this S with AS01 adjuvant in a vaccination challenge study in four K18-hACE2 transgenic mice (Fig. 2b). After two intramuscular immunizations with 5 μg adjuvanted S, we measured virus-neutralizing activity in sera of the vaccinated mice. Two mice (M3 and M4) had detectable neutralizing antibody responses, both with a reciprocal serum dilution titer of 15. There were no measurable amounts of neutralizing antibodies in the other two animals (M1 and M2) or in the sera obtained after the first immunization. Mice were challenged with an intranasal sublethal dose of SARS-CoV-2 at 18 weeks postprime. Two mice, M1 and M2, developed disease symptoms and showed a loss of body weight, in contrast to the exposed-immune control group (Fig. 2c). At 5 days postchallenge, SARS-CoV-2 virus was found in their lungs, nasal turbinate, and brains (Fig. 2d). This demonstrates SARS-CoV-2 infection and replication in the vaccinated




FIG 1 Expression of recombinant SARS-CoV-2 spike protein in insect cells. (a) In this study, recombinant baculoviruses were constructed containing spike proteins as schematically represented. (b) S full-length and S (delta TM) were detected inside Sf9 cells after staining with rabbit polyclonal sera against S1 (anti-S1) or cytoplasmic tail in S2 (anti-CT) or with human convalescent-phase sera obtained from two hospitals (EMC and Isala). pAb, polyclonal antibody.

K18-hACE2 mice (50, 51), similar to the nonvaccinated controls (Fig. 2d). M3 and M4 were protected from clinical COVID-19 disease and weight loss similar to the exposed-immune control group (Fig. 2c). Although no SARS-CoV-2 was detected in the lungs, virus was measured in the nasal turbinate of M3 and in the brains of both M3 and M4 (Fig. 2d). As a result, two intramuscular doses of adjuvanted S could provide partial protection against SARS-CoV-2 in hACE2 mice.

Production of strep-tagged S1 subunit increases yield and purity. We next aimed to produce the S1 subdomain to improve protein yield and purity after purification. Moreover, the adjuvanted spike subunit vaccine did not completely inhibit viral infection in K18-hACE2 transgenic mice. To improve the immunogenicity of the S1 antigen, the nanoparticle-based AP205 VLP display system was used. The secreted S1 (Fig. 1a, Sp53) was produced with AcOET-Sp53 baculoviruses in ExpiSf9 cells in shake flasks. SDS-PAGE and Western blot analyses showed that S1 was successfully expressed and secreted into the culture fluid (Fig. 3a) and could be purified efficiently using strep-tag affinity chromatography (Fig. 3b). The strep-tag affinity column had a higher specificity than the His-tag nickel affinity column and resulted in a relatively pure S1 protein compared to the purity of S after immobilized-metal affinity chromatography. The C-




FIG 2 Production of S and immunization of K18-hACE2 mice with two doses of adjuvanted S induce limited nAb responses and result in partial protection from SARS-CoV-2 challenge. (a) S was produced with the ExpiSf expression system and purified from medium. The elution fractions were pooled and analyzed on SDS-PAGE (stain-free) and Western blotting (anti-S1) in a serial dilution. (b) K18-hACE2 mice ($n = 4$, M1 to M4) were immunized with two doses of $5 \mu\text{g}$ S and AS01 adjuvant, where blood was collected after each vaccination. At 18 weeks postprime, the mice were challenged intranasally with SARS-CoV-2. (c) From 0 to 5 days postchallenge (dpc), body weight change was monitored. (d) At 5 dpc, the viremia in lungs, nasal turbinates, and brain were measured. Mice vaccinated with UV-inactivated SARS-CoV-2 served as an exposed immune control ($n = 3$, C1-C3), and nonvaccinated controls ($n = 12$) were included in viremia titrations.

terminal strep-tag was removed by tobacco etch virus (TEV) protease cleavage, resulting in TEV-cleaved S1 (60%) and an S1 aggregate (30%) (Fig. S2). Removal of the strep-tag was demonstrated by a shift in protein size on SDS-PAGE and a loss of signal from StrepTactin-alkaline phosphatase (AP) antibody on Western blotting (Fig. 3c). Both S1 and the S1 aggregate fractions show a band with the same mass on denaturing SDS-PAGE and binding on Western blotting to rabbit-anti-S1 and several human COVID-19 convalescent-phase sera (Fig. 3d). Moreover, S1 has a high binding affinity to immobilized ACE2, with a dissociation constant (k_D) of 16.7 nM (Fig. 3e), which is in a similar range as previously reported (10, 34, 52). This indicates that the receptor-binding site within S1 is exposed and available to interact with ACE2.

The secreted S1 production was further scaled up from shake flasks to a 3-liter bioreactor system infected at low multiplicity of infection (MOI). Cells were grown for 3 days before infection with baculovirus. The reactor was monitored continuously online using a holographic microscope and was sampled daily for offline measurements. The maximum viable cell density (VCD) was monitored both online and offline and peaked at 3 dpi (Fig. 3f). At 4 dpi, all detected cells showed signs of baculovirus infection (Fig. 3g). The bioreactor was harvested at 5 dpi when viability dropped below 70%. The culture fluid then contained 7 mg/liter S1, which further increased to 11 mg/liter during subsequent shake flask cultivation (Fig. 3g). This is a substantial increase in protein yield compared to the 0.18 mg/liter that was obtained for the S protein.

Analyses of S1 structure, folding, and glycosylation. The structure, folding, and glycosylation of insect cell-derived S1 were analyzed by several methods. The secondary structure content was calculated from the far-UV circular dichroism (CD) spectrum of S1 (Fig. 4a). With 6.8% α -helices and 38.4% β -sheets, the secondary structure content of S1 was highly similar to what was expected based on the wild-type (WT) SARS-CoV-2 spike structure (Fig. 4b and c) (i.e., 2.3% helices, 41.2%




FIG 3 Production and analyses of recombinant S1 protein in shake flasks and bioreactor. (a) S1 was produced with the ExpiSf9 expression system in chemically defined medium and was detected in cells and culture fluid on SDS-PAGE (stain-free) and Western blot (anti-S1). (b and c) S1 was purified from the culture fluid (b) and fractions before strep-tag removal (S1-strep) and after (S1 and S1 aggregate) were analyzed (c). (d) S1 and S1 aggregate (S1 aggr.) bind to COVID-19 convalescent-phase sera from Isala Zwolle (serum numbers 2, 3, 4) or from EMC Rotterdam (serum numbers 8, 9, 10) on Western blot. COVID-19 naive serum served as a negative control (Isala 7) and rabbit-anti-S1 (Sino Biological) as a positive control. (e) S1 also binds to immobilized ACE2, where real-time binding (black curves) was fitted in a 1:1 simple binding model (red curve). (f and g) Production of S1 was scaled up from shake-flask cultures to a 3-liter bioreactor. At time -3 days, ExpiSf cells were seeded, at $t = 0$ (straight line), and the cells were infected at an MOI of 0.01. The reactor was harvested at 5 dpi (dotted line), where 60 ml of the culture was transferred to a shake flask and continued (offline) sampling. (f) Viable cell density (VCD) and viability were monitored continuously (line), and samples were taken daily for extra offline measurements (dots). (g) Fraction of infected cells from total cells in the bioreactor and SARS-CoV-2 spike protein secreted in the culture supernatant measured by ELISA in milligrams per liter of culture.




FIG 4 Analysis of glycosylation and oligomerization of Sf9-cell-produced S1 protein. (a) Far-UV CD spectrum of S1 at 20°C and the resulting percentage of helices, sheets, and other structures within S1. (b) Data derived from CD measurements (experimental) were compared to those from wild-type S1 (crystal structure). (c) The proposed structure of S1 in trimeric conformation, based on the truncation of the full-length SARS-CoV-2 structure (77). (d) A representative chromatogram of S1 on a Superdex 200 increase 10/30 column, as detected by differential refractive index (dRI), absorption at 280 nm (A280), and light scattering (LS). The molecular weight of the species eluting in each indicated peak is shown in orange (conjugate mass). (e) S1 N-linked glycosylation was further confirmed by PNGase-F treatment and PAS staining. TEV-cleaved S1 was treated with PNGase-F. Treated (+) and nontreated (–) samples were analyzed on SDS-PAGE (stain-free) and Western blot (anti-S1). Glycosylation was confirmed by PAS stain.

sheets). Thus, CD confirms that at 20°C the purified spike S1 domain mostly retained its structural elements.

The oligomerization state, molar mass, and glycosylation of S1 were determined by duplicate size-exclusion chromatography coupled with multiangle light scattering (SEC-MALS) experiments. Three oligomerization states could be distinguished in the chromatograms, as monitored by absorbance of UV light at 280 nm (Abs280), refractive index (dRI), and light scattering (LS) (Fig. 4d, Fig. S3). Conjugate analysis revealed that peak 1 represented a glycosylated protein species with a molecular weight of 90.9 ± 0.2 kDa. This glycosylated protein consisted of a protein component ($82.4\% \pm 1.1\%$) with a molecular weight of 74.9 ± 1.0 kDa and a glycan component ($17.6\% \pm 1.1\%$) with a molecular weight of 16.0 ± 0.2 kDa. The molecular weight of the protein component in peak 1 is in good agreement with the 77.1 kDa that is expected for the S1 protein monomer based on the amino acid sequence. The dn/dc value (i.e., the refractive index increment) for the conjugate (i.e., 0.1775 ml/g) was obtained and was used to calculate the molecular weights of the species in elution peaks 2 and 3. The protein species were found to be 183.4 ± 0.4 kDa for peak 2 and 279.8 ± 1.6 kDa for peak 3. Thus, the protein species eluting in peaks 1, 2, and 3 corresponded to an S1 monomer, dimer, and trimer, respectively. Under these conditions, the monomer is clearly the predominant S1 form.

Glycosylation of S1 was further confirmed by PNGase-F treatment and Periodic acid-Schiff (PAS) staining of the protein. The PNGase-F treatment, which removes N-linked glycans, caused a shift in protein migration on SDS-PAGE gel and a loss of PAS staining of the Western blot membrane (Fig. 4e). Together, they substantiate the results obtained with SEC-MALS. Thus, S1 produced in Sf9 cells is heavily glycosylated, akin to SARS-CoV-2 proteins that were produced in HEK293 cells (53).

Display of S1 on AP205 VLPs. To improve the immunogenicity of the prototype vaccine, the S1 and S1 aggregate fractions were individually mixed in equimolar ratios with catcher-VLPs in an overnight coupling reaction (Fig. 5a). We included the S1 protein that still contained the C-terminal strep-tag (S1-strep) as a control. The coupling efficiency was assessed on a reducing SDS-PAGE as shown in Fig. 5b. An additional band of higher molecular mass appeared on the SDS-PAGE gel, corresponding to one S1 molecule covalently bound to one AP205 capsid. Removal of the C-terminal strep-tag by TEV protease cleavage improved the coupling efficiency. In that case, the coupling efficiency was estimated as at least 10%. This suggests that, on average, each VLP displayed at least 18 S1 proteins on its surface. A centrifugation step after coupling (stability spin test) revealed that the coupling was stable and the S1-VLP was not prone to aggregation. These results are similar to what was seen for a previously developed RBD-VLP vaccine (34). After purification of the VLPs from the remaining soluble S1, the VLPs are intact and of good quality, and the S1 domains are uniformly distributed among the VLP particles, as seen by transmission electron microscopy (TEM) (Fig. 5c).

Immunogenicity of the S1-VLP nanoparticle vaccine. The immunogenicity of the S1-VLP was assessed in a mouse immunization study and was compared to mice vaccinated with soluble S1 protein. Before vaccine formulation of S1-VLP, the unbound S1 was removed from the coupling reaction mix by using ultracentrifugation. BALB/c mice ($n = 4$) received two intramuscular immunizations containing only 0.5 μg S1-VLP or 0.5 μg S1 per dose, formulated with Addavax, and blood was collected 2 weeks after each vaccination (Fig. 5d). All mice showed potent immune responses, especially after the second immunization, as measured in an IgG protein enzyme-linked immunosorbent assay (ELISA) (Fig. 5e). The areas under the curve (AUC) were derived from the ELISA data and showed a slight difference in IgG levels after the first immunization between the two groups, with the S1-VLP vaccine performing better (Fig. 5f). After the second immunization, however, the effect of the VLP coupling was less clear, possibly because in both groups an adjuvant was used.

These sera were compared to sera of mice vaccinated with 5 μg of the previously developed RBD-VLP vaccine (34). Even though the antigen concentration in the S1-VLP vaccine trial was 10-fold lower, all groups had comparably high antibody responses to the spike protein, as determined by ELISA (Fig. 5g). The IgG titers specific for the SARS-CoV-2 RBD domain were higher in the RBD-VLP vaccinated mice than our S1- and S1-VLP-vaccinated mice after the first bleed but not after the second bleed (Fig. 5h).

Finally, after the second vaccination, all sera contained substantial virus-neutralizing antibody titers against the Wuhan (L008) SARS-CoV-2 strain, on which the vaccine was based (Fig. 5i). Importantly, sera were also able to neutralize the UK (B.1.1.7) strain of SARS-CoV-2 (Fig. 5j).

DISCUSSION

The development and/or improvement of effective SARS-CoV-2 vaccines are still a priority worldwide. Protein-based vaccines are needed to vaccinate the world population and to boost immunity against emerging variants. These vaccines are known for their inherent long-term safety and efficacy after administration and lack of preexisting antivector immunity (54). Moreover, the production safety, production costs, and vaccine storage temperatures are advantageous compared to mRNA and adenovirus vector vaccines, especially for scale-up manufacturing and global distribution (55). In this study, we have used the versatile and scalable baculovirus expression vector system to generate a two-component nanoparticle vaccine that induced a potent neutralizing antibody response against SARS-CoV-2 variants.




FIG 5 Low-dose vaccination of BALB/c mice with soluble S1 and S1-VLP induces potent neutralizing antibody responses. (a) S1 was coupled to VLPs by a coupling reaction as schematically represented. The catcher-VLPs are mixed with tag-S1, which results in a covalent display (decorated S1-VLP) that is visible on a reduced, denaturing SDS-PAGE gel. The individual components (catcher-VLP and S1) are shown. (b) Antigens were mixed with VLP and were analyzed again before (–) and after (+) a centrifugation step. An extra band appears representing the covalently fused S1 to a single AP205 capsid (S1-capsid). (c) The VLPs were purified from the uncoupled S1 subunits and visualized by negative-stain transmission electron microscopy (TEM). The scale bar represents 50 nm. (d) BALB/c mice ($n = 4$ per group) were vaccinated with 0.5 μ g soluble S1 or 0.5 μ g S1-VLP with Addavax adjuvant. Blood was collected 2 weeks postprime (1st bleed) and 2 weeks postboost (2nd bleed). (e) IgG antibodies against SARS-CoV-2 spike were analyzed in a dilution series in an ELISA. (f to h) The IgG titers were expressed (Continued on next page)

Both secreted S and S1 were produced with the ExpiSf9 expression system in chemically defined medium, which is both serum-free and protein-free. A yield after purification of 0.18 mg/liter for S was obtained. This is relatively low, although production yields of prefusion-stabilized S vary greatly between expression systems. Yields of 0.5 mg/liter S have been reported for FreeStyle 293 cells (10), 5 mg/liter for HEK293 cells (56), and up to 200 mg/liter for stably transfected CHO cells (57). Whereas trimeric S is often unstable (58, 59), smaller spike protein domains, for example, S1 or RBD, are generally more stable and result in higher yields. RBD is produced up to 50 to 60 mg/liter in Schneider-2 insect cell lines and Expi239F cells, respectively (34, 43), but production yields of the S1 subunit have not been reported to our knowledge. During our scale-up of S1 production in a stirred-tank bioreactor, we measured a maximum yield of 11 mg/liter culture, which might be further increased by subsequent parameter optimization that could be facilitated by online monitoring of the baculovirus infection process. The clear advantages of baculovirus expression over other expression platforms are its excellent safety profile, the rapid scalability to bioreactors up to several thousand liters, and its demonstrated use in the production of protein and VLP-based human vaccines (18, 19, 30). Based on the dosage of SARS-CoV-2 subunit vaccines in current phase 3 clinical trials (5 μ g/dose, Novavax, Clinical Trials registration no. NCT04583995; 10 μ g/dose, Sanofi Pasteur, Clinical Trials registration no. NCT04904549) and a licensed subunit vaccine made with the BEVS (135 to 180 μ g/dose; FluBlok [60]), a million-dose vaccine batch of S1-VLP theoretically can be produced in a single insect cell bioreactor. Moreover, as demonstrated for the Flublok influenza vaccine, the production process can easily be adapted to new protein variants in only 6 weeks (30, 61).

Using multiple analyses, we have demonstrated correct folding, ACE2 affinity, and extensive glycosylation of the insect cell-derived S1. While glycosylation patterns in insect cells are less complex and more homogeneous than in mammalian expression systems (53, 62), there are no indications that insect glycosylation patterns positively or negatively affect the immunogenicity of SARS-CoV-2 or other glycoprotein-based vaccines (13, 17, 31).

In a first attempt to investigate the immunogenicity of insect cell-derived SARS-CoV-2 antigen, adjuvanted S was tested in a vaccination-challenge experiment in K18-hACE2 transgenic mice, but only partial protection against sublethal SARS-CoV-2 challenge was obtained. The impurities in the His-tag-purified S subunit, including glycosylated insect cell proteins, lower the effective dose to induce a specific antibody response against S. This is in line with clinical studies in which low immune responses of baculovirus-expressed, adjuvanted S protein subunit in certain age groups were reported, and this may lead to a higher reactogenicity of the vaccine (35). Thus, a better SARS-CoV-2 antigen presentation was needed, and this was accomplished by coupling S1 subunits to AP205 VLPs (34).

The tag/catcher coupling of S1 to the VLPs was increased after removal of the strep-tag and was estimated to be at least 10%. Display of the SARS-CoV-2 RBD domain onto AP205 VLPs showed 33 to 45% coupling efficiency (34), and display of other proteins ranged from 22 to 88%, which negatively correlated with the size of the antigen (45). The coupling efficiency might be further improved by increasing the coupling pressure where the antigen is present in excess in the mixture. The coupling also is potentially facing partial steric hindrance between the relatively large, glycosylated S1 antigens, and it may be useful in future studies to experiment with flexible linkers at the S1 C terminus to provide additional space to further improve antigen coupling.

FIG 5 Legend (Continued)

as area under the curve (AUC) values. (f) The IgG titers in plates coated with SARS-CoV-2 spike were compared for mice vaccinated with S1 or S1-VLP. (h and g) Sera were measured on ELISA plates coated with RBD (g) or coated with full spike (h) and were compared to sera of mice vaccinated twice with 5 μ g RBD-VLP. (i and j) The reciprocal neutralizing antibody titers after the second vaccination are shown for neutralizing SARS-CoV-2 Wuhan (L008) (i) or UK/B.1.1.7 (j) strain. A two-sided nonparametric Mann-Whitney *t* test was used for statistical comparison. ns, nonsignificant; *, *P* < 0.05. Significance is marked with an asterisk in panels e (*P* = 0.0286) and g (*P* = 0.0159).

Moreover, S1 is highly glycosylated, and these glycans might further impair efficient coupling by steric hindrance between S1 domains. We have displayed an average of 18 relatively large S1 proteins on each 30-nm VLP, which is spaced comparably to the spikes on the wild-type SARS-CoV-2 virion (52, 63, 64).

The S1-VLPs (and S1 subunit for comparison) were used to immunize BALB/c mice twice with a low dose of 0.5 μg per mouse. The vaccines were adjuvanted with AddaVax, an MF59-like oil-in-water emulsion. Comparison between adjuvants in SARS-CoV-2 subunit vaccines has shown that these squalene-based oil-in-water emulsions are among the most potent adjuvants (16, 44, 65). An adjuvanting effect of the VLP was observed only after the first immunization, where a significant difference between the S1 subunit and S1-VLP was observed in the amount of IgG produced. After the second immunization, the S1 subunit and S1-VLP performed similarly in inducing potent immune responses. The boosting effect of the second immunization and the addition of Addavax adjuvant in both vaccine groups might be obscuring the intrinsic adjuvanting effect of the AP205 VLP (42).

An RBD-VLP prototype vaccine is currently under evaluation in the COUGH-1 clinical phase I/II trial (National Library of Medicine, Clinical Trials registration no. NCT04839146) and makes use of the same AP205 VLPs but with an RBD antigen expressed in S2 *Drosophila* cells (34). We show that our S1-VLP vaccine reaches IgG titers comparable to those of the RBD-VLP but with a 10-times-lower antigen dose (0.5 μg for S1-VLP versus 5 μg for RBD-VLP). In line with this result, a comparison of HEK293-cell-derived S1 and RBD subunits showed that S1 gave superior immune responses when formulated as a subunit vaccine (33). It remains to be seen if enhanced immunogenicity of S1 compared to RBD can compensate for the less efficient S1-VLP coupling. In our study, both vaccines appear equally potent in generating SARS-CoV-2-specific antibodies.

Neutralizing antibodies are an important immune correlate of protection (6, 66, 67); therefore, it was an important finding that all mice generated high neutralizing antibody titers for both the Wuhan L008 as well as the B.1.1.7 UK variant of SARS-CoV-2. The neutralizing antibody titer determinations have been performed in separate assays and, thus, cannot be directly compared, but it is feasible that protection against B.1.1.7 is somewhat reduced due to the presence of several mutations in the S1 domain (HV69-70del, Y144del, N501Y, A570D, and D614G). With RBD-based vaccines, this difference would only be a single amino acid (N501Y) (68). Immunogenicity against current and emerging variants might be further improved by the development of a multi-valent vaccine, i.e., a VLP displaying a mixture of S1 variants. This can result in a more focused immune response toward conserved protein domains and broader protection against variants, as was shown for HIV (69). Neutralizing antibody responses against other SARS-CoV-2 variants of concern, like B.1.1.7, are important for future vaccine designs and for the progression of vaccine candidates through clinical trials toward licensing (70). With novel SARS-CoV-2 variants emerging in the years to come, these two-component nanoparticle vaccines can be quickly adapted as booster vaccines by simply updating the antigen component.

MATERIALS AND METHODS

Insect cells. *Spodoptera frugiperda* Sf9 insect cells were cultured in Sf900II serum-free medium (Gibco, Thermo Fisher) with 50 $\mu\text{g}/\text{ml}$ gentamicin. ExpiSf9 cells were cultured in ExpiSf chemically defined medium (CDM) (Thermo Fisher). Both cell lines were cultured in suspension in shaker flasks at 27°C and 110 rpm in an orbital shaker.

Plasmid design and construction. All constructs are based on the SARS-CoV-2 Wuhan isolate (accession no. QIA20044.1) spike gene that was codon optimized for production in *Drosophila melanogaster* (34). For endoplasmic reticulum (ER) translocation and secretion, the native N-terminal signal sequence was replaced with either the Honeybee Melittin (HBM) or AcMNPV GP64 signal sequence. PCR was performed on either the wild-type spike sequence or the prefusion-stabilized sequence with primers found in Table S1 in the supplemental material (Q5 high-fidelity 2 \times master mix; New England BioLabs). All PCR products were flanked by Gateway AttB sites. The PCR products were gel purified with the Illustra GFX gel band purification kit (GE-Healthcare) and were then gateway cloned into the pDONR207 (Thermo Fisher), pDest8 (Thermo Fisher), and/or the pOET1 Gateway vectors (Oxford Expression Technologies) according to the protocol of Gateway cloning (Invitrogen).

Multiple constructs were designed based on the full-length spike (S full length), the prefusion stabilized secreted spike (S), and the S1 domain (Fig. 1a). First, the S full-length spike constructs contain the wild-type spike coding sequence (residues 16 to 1237) with an N-terminal HBM signal sequence (Sp1) or GP64 signal sequence (Sp2). Second, the S spike construct encodes an N-terminal HBM signal sequence, the prefusion stabilized ectodomain (residues 16 to 1208), a C-terminal T4 fibrin trimerization signal (T4 foldon), and an 8× histidine tag (His) (Sp9). Third, the S1 domain (residues 16 to 679) was PCR amplified and cloned into the pDONR207 vector. At the C terminus of the S1 gene in pDONR207, a synthetic DNA fragment (IDT DNA) was inserted by SapI restriction cloning (New England BioLabs). The resulting construct (Sp53) encodes the S1 domain with a C-terminal GSGSGS linker, the proprietary split-protein tag, tobacco etch virus (TEV) protease cleavage site (ENLYFQS), and triple strep-tag (WSHPQFEKGGGSGGGSSGSAWSHPQFEKGGGSGGGSSGSAWSHPQFEK).

Recombinant baculoviruses. Recombinant baculoviruses of *Autographa californica* multicausid nucleopolyhedrovirus (AcMNPV) were generated in two ways. First, pDest8 plasmids were transposed into *E. coli* cells containing bacmid AcBACe56 (Δ cc) (71) with the bac-to-bac baculovirus expression system (Invitrogen, Thermo Fisher), followed by transfection of the bacmid into insect cells with Expres2TR transfection reagent (Expres2ion Biotechnologies). Second, pOET1 plasmids were transfected into insect cells with the baculovirus genome AcOET (Δ cc Δ p10 Δ p74 Δ p26) with the *flashBAC* Ultra kit (Oxford Expression Technologies). Baculovirus stocks were amplified in ExpiSf9 cells, and viral titers were determined by endpoint dilution assay on Sf9-easy titer cells (72). Viral titers are defined as 50% tissue culture infectious dose (TCID₅₀) units per ml.

IAPMA. Production of S full-length in insect cells was assessed by immunoalkaline phosphatase monolayer assay (IAPMA). Sf9 cells were infected with recombinant baculovirus at a multiplicity of infection (MOI) of 1 TCID₅₀ per cell. At 3 days postinfection, cells were washed once with phosphate-buffered saline (PBS) and fixed in acetone-ethanol (1:1) fixative, followed by another wash step. Cells were incubated for 30 min at 37°C with one of the following primary antibodies: rabbit-anti-S1 (40591-T62; Sino Biological; binds the SARS-CoV-2 S1 domain), rabbit-anti-S2 (ab272504; Abcam; binds the cytoplasmic tail [CT] of S2), or human convalescent-phase sera (Isala Ziekenhuis, Zwolle; Erasmus Medical Centre, Rotterdam; obtained from COVID-19 patients). All primary antisera were diluted in PBS with 0.05% Tween 20 (Merck) and 5% skim milk powder (Campina, The Netherlands). Wells were washed once with PBS and incubated with alkaline phosphatase (AP)-conjugated goat-anti-rabbit or goat-anti-human secondary antibodies (Sigma). Proteins were detected by nitroterazolium blue–5-bromo-4-chloro-3-indolylphosphate (NBT-BCIP) staining (Roche Diagnostics GmbH, Basel, Switzerland), and cells were visualized by using a Zeiss AxioObserver Z1m inverted microscope.

Protein production in shake flasks. Recombinant proteins were produced with the ExpiSf expression system (Thermo Scientific). ExpiSf9 cells were grown in 1-liter shake flasks with 250 ml cell culture volume and were diluted to a density of 5×10^6 cells/ml in medium supplemented with ExpiSf enhancer. At 18 to 24 h after dilution, the cells were infected with recombinant baculovirus at an MOI of 4 to 5 TCID₅₀ units per cell. The flasks were incubated for 2 to 4 days until the viability was reduced to 70%. Next, phenylmethylsulfonyl fluoride (PMSF) protease inhibitor (Roche) was added at a final concentration of 170 μ g/ml. Cells were removed by centrifugation, and the pH of the resulting supernatant was increased to pH 7.8 by adding 0.1 M NaOH. The clarified supernatant was immediately used for purification or was stored at -80°C after the addition of glycerol (final concentration, 20%).

Protein production in insect-cell bioreactor. A 3-liter bioreactor (Applikon Biotechnology) with a 2-liter working volume was inoculated with 0.5×10^6 ExpiSf9 cells/ml at 99% viability. Cells were grown in CDM at 27°C with an agitation speed of 266 rpm. The dissolved oxygen (DO) was controlled at 30% air saturation by adding pure oxygen through a macroporous L-sparger. In addition, a constant headspace flow of 0.01-vvm air was applied. Cells were infected at an MOI of 0.01 at 3 days postinoculation at a VCD between 2.0×10^6 and 4.0×10^6 cells/ml. The reactor was harvested at 5 days postinfection (dpi) at a cell viability around 70% as described above. The reactor was monitored online continuously and was sampled daily for offline measurements. Sixty milliliters of cell culture was transferred to a shake flask during harvesting and was sampled for another 6 days. The VCD, viability, and fraction of infected cells were measured online by differential digital holographic microscopy (DDHM) with the iLine F holographic microscope (OVIZIO). The bioreactor samples were analyzed offline for VCD and viability by trypan blue exclusion by using a TC20 automatic cell counter (Bio-Rad). The SARS-CoV-2 spike S1 concentration in the medium was determined by protein ELISA (CBK4154; AssayGenie).

Protein purification. His-tagged S spike protein was purified from the clarified medium by using immobilized metal ion affinity chromatography (IMAC). The expression medium was clarified by centrifugation ($12,000 \times g$, 4°C). The clarified medium was loaded onto a Ni Sepharose excel (Cytiva) column that was equilibrated in equilibration buffer (20 mM Tris-Cl, 400 mM NaCl, pH 7.8). Non- and weakly bound contaminants were removed by washing with equilibration buffer. The bound proteins were eluted from the column by a 0 to 360 mM imidazole gradient in equilibration buffer. Eluted fractions were pooled and concentrated by using an Amicon Ultra-15 centrifugal filter unit (30 kDa; Merck). The concentrate was further purified by size-exclusion chromatography (SEC) with a Superdex S200 (Cytiva) column equilibrated with PBS buffer at pH 7.4. Eluted fractions were analyzed on SDS-PAGE. The fractions containing the S protein were pooled, concentrated, flash-frozen, and stored at -20°C .

Strep-tagged S1 spike protein was purified on a Strep-TactinXT superflow 5-ml cartridge (IBA GmbH). The clarified medium was treated with 15 μ l/ml BioLock biotin blocking solution (IBA) to remove free biotin. It was then loaded onto the Strep-Tactin column equilibrated in 100 mM Tris-HCl, 150 mM NaCl, and 1 mM EDTA, pH 8.0 (buffer W). The column was washed with buffer W, and proteins were eluted from the column in buffer W containing 50 mM biotin. To remove the triple strep-tag, we pooled

the eluted fractions and incubated them overnight at 4°C with TEV protease at a 10:1 (wt/wt) ratio in 50 mM Tris-Cl, 0.5 mM EDTA, and 1 mM dithiothreitol (DTT), pH 8.0. The protein was concentrated and further purified by using SEC as described above. Eluted fractions were analyzed with SDS-PAGE. The fractions containing S1 were pooled, flash-frozen, and stored at -20°C. Removal of the strep-tag by TEV cleavage was confirmed on Western blot immunodetection by Strep-Tactin AP-conjugated antibody (IBA Lifesciences).

SDS-PAGE and Western blot immunodetection. Protein samples were incubated in Laemmli buffer containing 5% β -mercaptoethanol for 10 min at 95°C and were separated on a 7.5% SDS-PAGE gel (Bio-Rad) or a 4 to 20% or 4 to 15% stain-free SDS-PAGE gel (containing photoactivatable trihalo compound; Bio-Rad). Proteins were visualized by 2.5-min UV-activated stain-free imaging (Bio-Rad GelDoc). The proteins in the gel then were blotted on a polyvinylidene difluoride (PVDF) or nitrocellulose membrane (Thermo Scientific, Bio-Rad). The membranes were blocked in PBS with 0.1% Tween 20 (PBST) supplemented with 3% skim milk powder (Campina, The Netherlands), and recombinant spike proteins were detected by immunodetection. As primary antibodies, we used rabbit-anti-S1 polyclonal serum diluted 1:3,000-1:5,000 (40591-T62; Sino Biological) or human COVID-19 convalescent-phase sera diluted 1:500 (Isala Ziekenhuis, Zwolle) or 1:1,000 (Erasmus Medical Centre, Rotterdam).

Detection was performed with either AP-conjugated secondary antibody or horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1:2,500 in PBST. The AP-conjugated goat-anti-rabbit (Aligent) and AP-conjugated goat-anti-human (Sigma-Aldrich) were detected by conversion of NBT-BCIP staining (Roche Diagnostics GmbH, Basel, Switzerland). HRP-conjugated goat-anti-rabbit (Sanbio) was visualized by Clarity Western ECL substrate (Bio-Rad) by using a Chemidoc MP (Bio-Rad). The strep-tag was detected by immunodetection with Strep-Tactin AP according to the manufacturer's protocol (2-1503-001; IBA Lifesciences).

PNGase treatment and PAS stain. The glycosylation status of recombinant spike proteins was analyzed by a PNGase treatment and PAS staining. Protein samples were incubated with PNGase-F (P0704; New England Biolabs) for 1 h at 37°C under denaturing conditions as described by the manufacturer. PNGase-F-treated and nontreated samples were analyzed by SDS-PAGE and Western blotting. Next, protein glycosylation was confirmed by PAS staining of the Western blot membrane. The PVDF membrane was soaked in PAS solution (1% periodic acid in 3% acetic acid) for 15 min. The membrane was washed twice with water and incubated for 15 min with Schiff's reagent (Sigma-Aldrich). The membrane was washed once in 0.5%, wt/vol, sodium bisulfite for 5 min and rinsed with demineralized water before imaging.

Far-UV CD spectroscopy. The structural features of the insect cell-produced S1 were assessed by far-UV circular dichroism (CD). Purified S1 was diluted to 1.3 μ M in PBS. The far-UV CD was measured by using a Jasco J715 spectropolarimeter at 20°C with 1-mm quartz cuvettes. Spectra were obtained by averaging 30 scans and were background corrected by subtracting the far-UV CD spectrum of 30 scans of PBS acquired under identical conditions. We used the CD data as the input for the BeStSel webserver (73, 74) to acquire the secondary structure content of S1. This was compared to the structural data of the S1 domain (derived from the wild-type spike protein structure) we obtained by the program STRIDE (75). In both algorithms, it was assumed that glycosylation and other protein modifications do not influence the amount of estimated secondary structures.

SEC-MALS. The molar mass, oligomerization state, and degree of glycosylation of S1 were determined by SEC-MALS. The S1 protein from the scaled-up production run was purified by Strep-Tactin purification followed by removal of the strep-tag by TEV protease incubation and SEC. After SEC, the second peak on the chromatogram (Fig. S2, elution 99 to 117 ml) was selected for SEC-MALS analyses to exclude large aggregates. An Infinity 1260 II high-performance liquid chromatography system (Agilent) was coupled to an Optilab dRI detector and miniDawn MALS detector (Wyatt Technologies, USA). The column thermostat and autosampler were both set to 20°C. The protein was diluted to 0.83 mg/ml in PBS (Sigma-Aldrich) and was then resolved in duplicate experiments on a Superdex 200 increase 10/30 GL column (GE Life Sciences) equilibrated in PBS. With ASTRA software (Wyatt Technologies), the absorption at 280 nm, light scattering, and refractive index properties of the eluates were collected and analyzed. The contribution of protein and glycosylation to the eluting species was determined by the conjugate analysis method in ASTRA using dn/dc values of 0.185 ml/g and 0.14 ml/g for protein and glycans, respectively, and an extinction coefficient for the protein at 280 nm of 1.2 ml/(mg·cm). The dn/dc value obtained for the conjugate was used for further molecular weight determination.

Ace2 binding kinetics. Interactions of S1 antigens with hAce2 protein were performed with a QCM Attana A200 Biosensor (Attana AB) as described elsewhere (34). Briefly, ExpreS²-expressed hACE2 at 50 μ g/ml (Expre2ion Biotechnologies) was immobilized on an LNB carboxyl chip. The binding of S1 proteins to the chip was measured in a 2-fold serial dilution series (200 nM to 6.25 nM) in PBS, pH 7.4.

Vaccinations at Queensland Institute of Medical Research Berghofer. Cytokeratin-18 promoter (K18)-hACE2 mice were housed at Queensland Institute of Medical Research Berghofer. K18 mice ($n = 4$) received two intramuscular administrations of 50 μ l vaccine, containing 25 μ l purified S and 25 μ l AS01 adjuvant. Blood was collected and tested for neutralizing antibodies against SARS-CoV-2 in a virus neutralization assay. The sera were diluted 1:10, and then 2-fold serial dilutions were incubated with 100 TCID₅₀ of SARS-CoV-2 (strain hCoV-19/Australia/QLD02/2020) for 2 h. Samples were added to Vero E6 cells in 96-well plates, and viral cytopathic effect (CPE) was quantified on day 4 by crystal violet staining. Mice vaccinated with UV-inactivated SARS-CoV-2 provided positive-control sera, and naive mice provided negative-control sera. At 18 weeks postprime, the mice were challenged intranasally with 5×10^4 TCID₅₀ SARS-CoV-2 per mouse (hCoV-19/Australia/QLD02/2020). Weight change was monitored for 5 days, and viral titers were determined in the lungs, brain, and nasal turbinate.

Coupling S1 antigen to virus-like particles. Catcher-VLPs based on the AP205 coat protein (gene ID 956335) fused to the proprietary catcher sequence were produced in *E. coli* (45). The purified S1 was coupled to the catcher-VLPs and formulated as an adjuvanted vaccine as previously described (34). In short, S1 and catcher-VLPs were mixed in a 1:1 molar ratio in PBS overnight at room temperature. A part of the mix was spun down at $16,000 \times g$ for 2 min to assess the stability of the coupled protein. Equal amounts of pre- and postspin samples were mixed with DTT and were heated prior to analyses by SDS-PAGE. The coupling efficiency was calculated as the percentage of AP205 capsids that had been conjugated to an S1 domain via tag-catcher interactions (76). The protein bands on the SDS-PAGE gel were analyzed by ImageQuantTL software to determine the band intensity. The band intensity of the VLP subunit before the coupling reaction was divided by the equivalent protein band after coupling and was multiplied by 100. After the coupling reaction, the S1-VLP was purified from the remaining coupling mixture. This was loaded onto an OptiPrep step gradient (23%, 29%, and 35%) (Sigma-Aldrich) and was centrifuged at 47,800 rpm for 3.30 h. Buffer exchange was then performed by dialysis in PBS.

TEM of the S1-VLP vaccine. The quality of the VLPs after coupling, purification, and buffer exchange was assessed by transmission electron microscopy (TEM). For this, 1 μ l VLP mixture was added to a carbon-coated copper grid and was incubated for 2 min at room temperature. The grid was washed once with Milli-Q water and was negatively stained for 30 s in 2% uranyl acetate and air-dried before observation with a JEOL 1400 plus transmission electron microscope.

Vaccinations at University of Copenhagen. Experiments were authorized by the Danish National Animal Experiments Inspectorate (license no. 2018-15-0201-01541; Dyreforsøgstilsynet) and performed according to national guidelines. Female BALB/c AnNRj mice were vaccinated with 0.5 μ g S1 ($n = 4$) or 0.5 μ g S1-VLP ($n = 4$) formulated in Addavax (Invivogen). Blood was collected 2 weeks after each immunization. The serum was isolated by two centrifugation steps at $800 \times g$ for 8 min at 8°C. Specific IgG titers in serum samples were measured by ELISA. For this, the plates were coated with 0.1 μ g/well recombinant Expres^{S2}-produced spike protein or RBD (Expres2ion Biotechnologies). Serum samples were added at a starting dilution of 1:50 and added in 3-fold dilutions. IgG titers were determined by optical density measurements after incubation with HRP-conjugated goat anti-mouse IgG (A16072; Life Technologies). Plates were developed by using TMB X-tra substrate (4800A; Kem-En-Tec) and absorbance measurements at 450 nM. Virus-neutralizing antibody titers in the mouse sera were determined on Vero E6 cells as described elsewhere (34) with SARS-CoV-2 Wuhan (L008) or SARS-CoV-2 UK/B.1.1.7 (VOC-202012/01) at 120 TCID₅₀/well.

Data availability. Data are provided within this paper and are available from the authors upon reasonable request.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 2.4 MB.

FIG S2, TIF file, 2.3 MB.

FIG S3, TIF file, 2.9 MB.

TABLE S1, DOCX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank Els Roode, Gwen Nowee, Marleen Abma-Henkens, and Jelmer Vroom (Laboratory of Virology, Wageningen University) for their technical assistance. We acknowledge Corine Geurts van Kessel and Marion Koopmans (Erasmus MC, Rotterdam, The Netherlands) and Jacky Flipse (Isala, Zwolle, the Netherlands) for sharing sera of COVID-19 convalescent patients. We also acknowledge Arthur Oudshoorn (Applikon Biotechnology) for his assistance in the bioreactor production runs. This research was funded through European Union's Horizon 2020 research and innovation program (grant agreement no. 101003608) and conducted in the H2020 Prevent-nCoV consortium.

All authors contributed to discussing the experimental setup and data. All authors have read and agreed to the written version of the manuscript. L.V.O. and G.P.P. designed the constructs and M.S., Ali Salanti, W.A.D.J., and A.F.S. provided input. L.V.O. and C.G. cloned and generated the recombinant baculoviruses. J.A., W.A.C.E., F.V.D.E., T.K., and D.E.M. designed and/or performed the shake flask and bioreactor production runs. D.C.S., W.A.C.E., M.H.M.E., A.H.W., S.L., and W.V.D.B. contributed to the downstream processing of the proteins. A.H.W. and S.L. performed the CD and SEC-MALS analyses. L.D., C.G., and L.V.O. analyzed protein samples on Western blotting. Andreas Suhrbier and T.T.L. performed the K18-hACE2 vaccination challenge study. R.D. measured and analyzed the ACE2 binding kinetics. C.F. performed the VLP coupling, the mouse immunizations, and serum ELISA. M.K., S.T.M., and S.K.M. measured virus neutralization

of serum samples. W.A.D.J., Ali Salanti, M.A.N., and A.F.S. were involved in funding acquisition and supervision within the consortium. M.M.V.O., D.W., and R.H.W. contributed supervision and funding acquisition within Wageningen University. L.V.O. and G.P.P. wrote the manuscript with input from D.M., J.A., C.F., S.T.M., M.A.N., D.C.S., A.H.W., S.L., and L.D.

A.F.S., A.S., and M.A.N. are listed as coinventors on a patent covering the AP205 CLP vaccine platform technology (WO2016112921 A1) licensed to AdaptVac, and C.F. and W.A.D.J. are employees at this company. The other authors declare no conflict of interest.

REFERENCES

- Carvalho T, Krammer F, Iwasaki A. 2021. The first 12 months of COVID-19: a timeline of immunological insights. *Nat Rev Immunol* 21:245–256. <https://doi.org/10.1038/s41577-021-00522-1>.
- Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res* 176:104742. <https://doi.org/10.1016/j.antiviral.2020.104742>.
- Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 183:1735. <https://doi.org/10.1016/j.cell.2020.02.058>.
- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579:270–273. <https://doi.org/10.1038/s41586-020-2012-7>.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181:271–280. <https://doi.org/10.1016/j.cell.2020.02.052>.
- Addetia A, et al. 2020. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. *J Clin Microbiol* 58:e02107-20. <https://doi.org/10.1128/JCM.02107-20>.
- Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS, Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L, Van Ry A, Blade K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z, Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt AG, Wesemann DR, Baric RS, et al. 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* 369:806–811. <https://doi.org/10.1126/science.abc6284>.
- Kirchdoerfer RN, et al. 2018. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. *Sci Rep* 8:15701. <https://doi.org/10.1038/s41598-018-34171-7>.
- Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong W-P, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A* 114:E7348–E7357. <https://doi.org/10.1073/pnas.1707304114>.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 367:1260–1263. <https://doi.org/10.1126/science.abb2507>.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WW, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin KU, Gruber WC, C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 383:2603–2615. <https://doi.org/10.1056/NEJMoa2034577>.
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupshael N, Creech CB, McGgettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 384:403–416. <https://doi.org/10.1056/NEJMoa2035389>.
- Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truysers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M, ENSEMBLE Study Group. 2021. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. *N Engl J Med* 384:2187–2201. <https://doi.org/10.1056/NEJMoa2101544>.
- Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoun R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. 2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. *Nat Commun* 12:372. <https://doi.org/10.1038/s41467-020-20653-8>.
- Guebre-Xabier M, Patel N, Tian J-H, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. 2020. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. *Vaccine* 38:7892–7896. <https://doi.org/10.1016/j.vaccine.2020.10.064>.
- Liang JG, Su D, Song T-Z, Zeng Y, Huang W, Wu J, Xu R, Luo P, Yang X, Zhang X, Luo S, Liang Y, Li X, Huang J, Wang Q, Huang X, Xu Q, Luo M, Huang A, Luo D, Zhao C, Yang F, Han J-B, Zheng Y-T, Liang P. 2021. S-trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. *Nat Commun* 12:1346–1312. <https://doi.org/10.1038/s41467-021-21634-1>.
- Keach C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. 2020. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N Engl J Med* 383:2320–2332. <https://doi.org/10.1056/NEJMoa2026920>.
- Felberbaum RS. 2015. The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors. *Biotechnol J* 10:702–714. <https://doi.org/10.1002/biot.201400438>.
- Van Oers MM, Pijlman GP, Vlak JM. 2015. Thirty years of baculovirus-insect cell protein expression: from dark horse to mainstream technology. *J Gen Virol* 96:6–23. <https://doi.org/10.1099/vir.0.067108-0>.
- Zhou Z, Post P, Chubet R, Holtz G, McPherson C, Petric M, Cox M. 2006. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. *Vaccine* 24:3624–3631. <https://doi.org/10.1016/j.vaccine.2006.01.059>.
- Chun J, Cho Y, Park KH, Choi H, Cho H, Lee H-J, Jang H, Kim KH, Oh Y-K, Kim YB. 2019. Effect of fc fusion on folding and immunogenicity of middle east respiratory syndrome coronavirus spike protein. *J Microbiol Biotechnol* 29:813–819. <https://doi.org/10.4014/jmb.1903.03043>.
- Kato T, Takami Y, Kumar Deo V, Park EY. 2019. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. *J Biotechnol* 306:177–184. <https://doi.org/10.1016/j.jbiotec.2019.10.007>.

23. Fan X, Cao D, Kong L, Zhang X. 2020. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. *Nat Commun* 11:3618. <https://doi.org/10.1038/s41467-020-17371-6>.
24. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. 2020. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* 117:11727–11734. <https://doi.org/10.1073/pnas.2003138117>.
25. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. 2020. Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581: 221–224. <https://doi.org/10.1038/s41586-020-2179-y>.
26. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 581:215–220. <https://doi.org/10.1038/s41586-020-2180-5>.
27. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuan K-Y, Wang Q, Zhou H, Yan J, Qi J. 2020. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell* 181:894–904. <https://doi.org/10.1016/j.cell.2020.03.045>.
28. Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R. 2013. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. *Viral Immunol* 26: 126–132. <https://doi.org/10.1089/vim.2012.0076>.
29. Li T, Zheng Q, Yu H, Wu D, Xue W, Xiong H, Huang X, Nie M, Yue M, Rong R, Zhang S, Zhang Y, Wu Y, Wang S, Zha Z, Chen T, Deng T, Wang Y, Zhang T, Chen Y, Yuan Q, Zhao Q, Zhang J, Gu Y, Li S, Xia N. 2020. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. *Emerg Microbes Infect* 9:2076–2090. <https://doi.org/10.1080/22221751.2020.1821583>.
30. Buckland B, Boulanger R, Fino M, Sirivastava I, Holtz K, Khamrtsov N, McPherson C, Meghrouh J, Kubera P, Cox MMJ. 2014. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. *Vaccine* 32:5496–5502. <https://doi.org/10.1016/j.vaccine.2014.07.074>.
31. Cox MMJ, Izikson R, Post P, Dunkle L. 2015. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. *Ther Adv Vaccines* 3:97–108. <https://doi.org/10.1177/2051013615595595>.
32. Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. 2014. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. *Pharmacoepidemiol Drug Saf* 23:456–465. <https://doi.org/10.1002/pds.3593>.
33. Wang Y, Wang L, Cao H, Liu C. 2021. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. *J Med Virol* 93:892–898. <https://doi.org/10.1002/jmv.26320>.
34. Fougeroux C, Goksøyr L, Idorn M, Soroka V, Myeni SK, Dagil R, Janitzek CM, Søgaard M, Aves K-L, Horsted EW, Erdoğan SM, Gustavsson T, Dorosz J, Clemmensen S, Fredsgaard L, Thrane S, Vidal-Calvo EE, Khalifé P, Hulen TM, Choudhary S, Theisen M, Singh SK, Garcia-Senosaiain A, Van Oosten L, Pijlman G, Hierzberger B, Domeyer T, Nalewajek BW, Strøbæk A, Skrzypczak M, Andersson LH, Buus S, Buus AS, Christensen JP, Dalebout TJ, Iversen K, Harritshøj LH, Mehmüller B, Ullum H, Reinert LS, de Jongh WA, Kikkert M, Paludan SR, Theander TG, Nielsen MA, Salanti A, Sander AF. 2021. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. *Nat Commun* 12:324. <https://doi.org/10.1038/s41467-020-20251-8>.
35. Goepfert PA, et al. 2021. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. *Lancet Infect Dis* [https://doi.org/10.1016/s1473-3099\(21\)00147-x](https://doi.org/10.1016/s1473-3099(21)00147-x).
36. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol* 10:787–796. <https://doi.org/10.1038/nri2868>.
37. Hua Z, Hou B. 2013. TLR signaling in B-cell development and activation. *Cell Mol Immunol* 10:103–106. <https://doi.org/10.1038/cmi.2012.61>.
38. López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. 2016. Self-assembling protein nanoparticles in the design of vaccines. *Comput Struct Biotechnol J* 14:58–68. <https://doi.org/10.1016/j.csbj.2015.11.001>.
39. Mohsen MO, Gomes AC, Vogel M, Bachmann MF. 2018. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. *Vaccines* 6:37. <https://doi.org/10.3390/vaccines6030037>.
40. De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. 2014. Long-term efficacy and safety of human papillomavirus vaccination. *Int J Womens Health* 6:999–1010. <https://doi.org/10.2147/IJWH.S50365>.
41. Schiller J, Lowy D. 2018. Explanations for the high potency of HPV prophylactic vaccines. *Vaccine* 36:4768–4773. <https://doi.org/10.1016/j.vaccine.2017.12.079>.
42. Zhang B, Chao CW, Tsybovsky Y, Abiona OM, Hutchinson GB, Moliva JI, Olia AS, Pegu A, Phung E, Stewart-Jones GBE, Verardi R, Wang L, Wang S, Werner A, Yang ES, Yap C, Zhou T, Mascola JR, Sullivan NJ, Graham BS, Corbett KS, Kwong PD. 2020. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. *Sci Rep* 10:18149. <https://doi.org/10.1038/s41598-020-74949-2>.
43. Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee E-C, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veelsler D, King NP. 2020. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. *Cell* 183: 1367–1382. <https://doi.org/10.1016/j.cell.2020.10.043>.
44. Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh C-L, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, et al. 2021. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. *Nature* 594: 253–258. <https://doi.org/10.1038/s41586-021-03530-2>.
45. Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert GJ, Sauerwein R, Schiller JT, Nielsen MA, Theander TG, Salanti A, Sander AF. 2016. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. *J Nanobiotechnol* 14:30. <https://doi.org/10.1186/s12951-016-0181-1>.
46. Li L, Fierer JO, Rapoport TA, Howarth M. 2014. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide tag. *J Mol Biol* 426:309–317. <https://doi.org/10.1016/j.jmb.2013.10.021>.
47. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. 2012. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesion. *Proc Natl Acad Sci U S A* 109: E690–E697. <https://doi.org/10.1073/pnas.1115485109>.
48. Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. 2016. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. *Sci Rep* 6: 19234–19213. <https://doi.org/10.1038/srep19234>.
49. Fredsgaard L, et al. 2021. Head-to-head comparison of modular vaccines developed using different capsid virus-like particle backbones and antigen conjugation systems. *Vaccines* 9:539. <https://doi.org/10.3390/vaccines9060539>.
50. Kumari P, Rothen HA, Natekar JP, Stone S, Pathak H, Strate PG, Arora K, Brinton MA, Kumar M. 2021. Neuroinvasion and encephalitis following intranasal inoculation of sars-cov-2 in k18-hace2 mice. *Viruses* 13:132. <https://doi.org/10.3390/v13010132>.
51. Moreau GB, Burgess SL, Sturek JM, Donlan AN, Petri WA, Mann BJ. 2020. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. *Am J Trop Med Hyg* 103:1215–1219. <https://doi.org/10.4269/ajtmh.20-0762>.
52. Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L, Nakane T, Zivanov J, Neufeldt CJ, Cerikan B, Lu JM, Peukes J, Xiong X, Kräusslich H-G, Scheres SHW, Bartenschlager R, Briggs JAG. 2020. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. *Nature* 588:498–502. <https://doi.org/10.1038/s41586-020-2665-2>.
53. Wang D, Baudys J, Bundy JL, Solano M, Keppel T, Barr JR. 2020. Comprehensive analysis of the glycan complement of SARS-CoV-2 spike proteins using signature ions-triggered electron-transfer/higher-energy collisional dissociation (ETHcD) mass spectrometry. *Anal Chem* 92:14730–14739. <https://doi.org/10.1021/acs.analchem.0c03301>.
54. Moore JP, Klasse PJ. 2020. COVID-19 vaccines: “warp speed” needs mind melds, not warped minds. *J Virol* 94:e01083-20. <https://doi.org/10.1128/JVI.01083-20>.
55. Nagy A, Alhatlani B. 2021. An overview of current COVID-19 vaccine platforms. *Comput Struct Biotechnol J* 19:2508–2517. <https://doi.org/10.1016/j.csbj.2021.04.061>.
56. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, Frank P, Denson J-P, Hong M, Gulten G, Sadtler K, Messing S, Gillette W. 2020. Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology

- assays. *Protein Expr Purif* 174:105686. <https://doi.org/10.1016/j.pep.2020.105686>.
57. Wu Y, Huang X, Yuan L, Wang S, Zhang Y, Xiong H, Chen R, Ma J, Qi R, Nie M, Xu J, Zhang Z, Chen L, Wei M, Zhou M, Cai M, Shi Y, Zhang L, Yu H, Hong J, Wang Z, Hong Y, Yue M, Li Z, Chen D, Zheng Q, Li S, Chen Y, Cheng T, Zhang J, Zhang T, Zhu H, Zhao Q, Yuan Q, Guan Y, Xia N. 2021. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. *Sci Transl Med* 13:eabg1143. <https://doi.org/10.1126/scitranslmed.abg1143>.
 58. Stuble M, Gervais C, Lord-Dufour S, Perret S, L'Abbé D, Schrag J, St-Laurent G, Durocher Y. 2021. Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells. *J Biotechnol* 326:21–27. <https://doi.org/10.1016/j.jbiotec.2020.12.005>.
 59. Juraszek J, Rutten L, Blokland S, Bouchier P, Voorzaat R, Ritschel T, Bakkers MJG, Renault LLR, Langedijk JPM. 2021. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat Commun* 12:244–248. <https://doi.org/10.1038/s41467-020-20321-x>.
 60. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M. 2007. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. *JAMA* 297:1577–1582. <https://doi.org/10.1001/jama.297.14.1577>.
 61. Cox MMJ, Hashimoto Y. 2011. A fast track influenza virus vaccine produced in insect cells. *J Invertebr Pathol* 107(Suppl):S31–S41. <https://doi.org/10.1016/j.jip.2011.05.003>.
 62. Harrison RL, Jarvis DL. 2006. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce “mammalianized” recombinant glycoproteins. *Adv Virus Res* 68:159–191. [https://doi.org/10.1016/S0065-3527\(06\)68005-6](https://doi.org/10.1016/S0065-3527(06)68005-6).
 63. Bachmann MF, Mohsen MO, Zha L, Vogel M, Speiser DE. 2021. SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. *NPJ Vaccines* 6:2–5. <https://doi.org/10.1038/s41541-020-00264-6>.
 64. Liu C, Mendonça L, Yang Y, Gao Y, Shen C, Liu J, Ni T, Ju B, Liu C, Tang X, Wei J, Ma X, Zhu Y, Liu W, Xu S, Liu Y, Yuan J, Wu J, Liu Z, Zhang Z, Liu L, Wang P, Zhang P. 2020. The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET. *Structure* 28:1218–1224. <https://doi.org/10.1016/j.str.2020.10.001>.
 65. Haun BK, Lai C-Y, Williams CA, Wong TAS, Lieberman MM, Pessaint L, Andersen H, Lehrer AT. 2020. CoVaccine HT adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 spike S1 immunization. *Front Immunol* 11:599587. <https://doi.org/10.3389/fimmu.2020.599587>.
 66. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, Pradenas E, Clotet B, Blanco J. 2021. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. *Biochem Biophys Res Commun* 538:187–191. <https://doi.org/10.1016/j.bbrc.2020.10.108>.
 67. Sui Y, Bekele Y, Berzofsky JA. 2021. Potential SARS-CoV-2 immune correlates of protection in infection and vaccine immunization. *Pathogens* 10:1–11. <https://doi.org/10.3390/pathogens10020138>.
 68. Socher E, Conrad M, Heger L, Paulsen F, Sticht H, Zünke F, Arnold P. 2021. Mutations in the B.1.1.7 SARS-CoV-2 spike protein reduce receptor-binding affinity and induce a flexible link to the fusion peptide. *Biomedicines* 9:525. <https://doi.org/10.3390/biomedicines9050525>.
 69. Brouwer PJM, Antanasijevic A, Berndsen Z, Yasmeen A, Fiala B, Bijl TPL, Bontjer I, Bale JB, Sheffler W, Allen JD, Schorcht A, Burger JA, Camacho M, Ellis D, Cottrell CA, Behrens A-J, Catalano M, Del Moral-Sánchez I, Ketas TJ, LaBranche C, van Gils MJ, Slieden K, Stewart LJ, Crispin M, Montefiori DC, Baker D, Moore JP, Klasse PJ, Ward AB, King NP, Sanders RW. 2019. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. *Nat Commun* 10:4272. <https://doi.org/10.1038/s41467-019-12080-1>.
 70. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shmelyovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* 592:616–622. <https://doi.org/10.1038/s41586-021-03324-6>.
 71. Pijlman GP, et al. 2020. Relocation of the attTn7 transgene insertion site in bacmid DNA enhances baculovirus genome stability and recombinant protein expression in insect cells. *Viruses* 12:1448. <https://doi.org/10.3390/v12121448>.
 72. Hopkins RF, Esposito D. 2009. A rapid method for titrating baculovirus stocks using the Sf-9 Easy Titer cell line. *Biotechniques* 47:785–788. <https://doi.org/10.2144/000113238>.
 73. Micsonai A, Wien F, Bulyáki É, Kun J, Moussong É, Lee Y-H, Goto Y, Réfrégiers M, Kardos J. 2018. BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. *Nucleic Acids Res* 46:W315–W322. <https://doi.org/10.1093/nar/gky497>.
 74. Micsonai A, Wien F, Kernya L, Lee Y-H, Goto Y, Réfrégiers M, Kardos J. 2015. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. *Proc Natl Acad Sci U S A* 112:E3095–E3103. <https://doi.org/10.1073/pnas.1500851112>.
 75. Frishman D, Argos P. 1995. Knowledge-based protein secondary structure assignment. *Proteins Struct Funct Bioinforma* 23:566–579. <https://doi.org/10.1002/prot.340230412>.
 76. Janitzek CM, Matondo S, Thrane S, Nielsen MA, Kavishe R, Mwakalinga SB, Theander TG, Salanti A, Sander AF. 2016. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. *Malar J* 15:545–549. <https://doi.org/10.1186/s12936-016-1574-1>.
 77. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. 2020. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat Struct Mol Biol* 27:763–767. <https://doi.org/10.1038/s41594-020-0468-7>.